Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: A double-blind, placebo-controlled study

Journal of Veterinary Internal Medicine

Volumn 21, Issue 1, 2007, Pages 141-148

  Chretin, J D ^a,d   Rassnick, K M ^a,e   Shaw, N A ^a   Hahn, K A ^b,f   Ogilvie, G K ^c,g   Kristal, O ^a   Northrup, N C ^a,h   Moore, A S ^a,i  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d Veterinary Centers of America   (United States)

^e Department of Obstetrics Gynecology   (United States)

^f GULF COAST VETERINARY SPECIALISTS   (United States)

^g California Veterinary Specialists   (United States)

^h UNIVERSITY OF GEORGIA   (United States)

ⁱ Veterinary Oncology Consultants   (Australia)

Author keywords

Antimicrobials; Doxorubicin; Gastrointestinal toxicity; Hospitalization; L asparaginase; Myelosuppression

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; PLACEBO; SULFADOXINE; SULFADOXINE PLUS TRIMETHOPRIM; TRIMETHOPRIM;

ANIMAL; ANIMAL DISEASE; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; LYMPHOMA; MALE; OSTEOSARCOMA; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; LYMPHOMA; MALE; OSTEOSARCOMA; PLACEBOS; SULFADOXINE; TRIMETHOPRIM;

ANIMALIA; CANIS FAMILIARIS;

EID: 33847072295     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2007)21[141:PTDCID]2.0.CO;2     Document Type: Article

References (50)

1. Moulton JE, Harvey JW. Tumors of lymphoid and hematopoietic tissue. In: Moulton JE, ed. Tumors of Domestic Animals, 3rd ed. Berkeley, CA: University of California Press; 1990:231-307.
2. Priester WA, McKay FW. The occurrence of tumors in domestic animals. Natl Cancer Inst Monogr 1980;54:1-210.
3. Withrow SJ, Powers BE, Straw RC, et al. Comparative aspects of osteosarcoma: Dog vs. man. Clin Orthop 1991;270:159-167.
4. Postorino NC, Susaneck SJ, Withrow SJ, et al. Single agent therapy with adriamycin for canine lymphsarcoma. J Am Anim Hosp Assoc 1989;25:221-225.
5. Berg J, Weinstein MJ, Springfield DS, et al. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555-1559.
6. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419-1426.
7. Gurwith MJ, Brunton JL, Lank BA, et al. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 1979;66:248-256.
8. Dekker AW, Rozenberg-Arska M, Sixma JJ, et al. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute non-lymphocytic leukemia. Ann Intern Med 1981;95:555-559.
9. Carlson JW, Folwer JM, Saltzman AK, et al. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol. Gynecol Oncol 1994;55:415-420.
10. Kurrle E, Dekker AW, Gaus W, et al. Prevention of infection in acute leukemia: A prospective randomized study on the efficacy of two different drug regimens for antimicrobial prophylaxis. Infection 1986;14:226-232.
11. Cullen MC, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. New Eng J Med 2005;353:988-998.
12. Owen LN, ed. TNM Classification of Tumours in Domestic Animals. Geneva: World Health Organization; 1980:46-47.
13. Enneking WF, Spanier SS, Goodman MA. A system for surgical staging of musculoskeletal sarcoma. Clin Orthop 1980;153: 106-120.
14. Donnelly JP, Maschmeyer G, Daenen S. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukemia-ciprofloxacin versus co-trimoxazole plus colistin. Eur J Cancer 1992;28(A):873-878.
15. Warren RE. Protecting neutropenic patients from bowel-derived organisms. J Hosp Infect 1991;19(C):43-58.
16. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-396.
17. Watson JG, Powles RG, Lawson DN, et al. Cotrimoxazole versus non-absorbable antibiotics in acute leukemia. Lancet 1982; 1:6-9.
18. EORTC International Antimicrobial Therapy Project Group, Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. J Infect Dis 1984;150:372-37.
19. Ekert H, Jurk IH, Waters KD, et al. Prophylactic cotrimoxazole and lactobacilli preparation in neutropenic patients. Med Pediatr Oncol 1980;8:47-54.
20. Polsky B, Armstrong D. Infectious complications of neoplastic disease. Am J Infect Control 1985;13:199-209.
21. Savage DC. Introduction to mechanisms of association on indigenous microbes. Am J Clin Nutr 1979;32:113-118.
22. Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia: Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972;77:707-714.
23. Waaij D. The colonization resistance of the digestive tract in experimental animals and its consequences for infection prevention, acquisition of new bacteria and the prevention of spread of bacteria between cage mates. In: Waaij D, Verhoef J, eds. New Criteria for the Antimicrobial Therapy: Maintenance of Digestive Tract Colonization Resistance, Excerpta Medica International Congress Series. Amsterdam, Netherlands: Elsevier Science; 1979: 43-53.
24. Myers NC III, Moore AS, Rand WA, et al. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 1997;11:333-339.
25. Cotter SM. Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone: I. Treatment of dogs. J Am Anim Hosp Assoc 1983;19:159-165.
26. Zemann BI, Moore AS, Rand WM, et al. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med 1998; 12:465-470.
27. Chun R, Garrett LD, Vail DM. Evaluation of a high dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000; 14:120-124.
28. Ogilvie GK, Richardson RC, Curtis CR, et al. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 1989;195:1584-1587.
29. de Lalla F. Antibiotic treatment of febrile episodes in neutropenic cancer patients: Clinical and economic considerations. Drugs 1997;53:789-804.
30. Northrup NC, Rassnick KM, Snyder LA, et al. Neutropenia associated with vincristine and L-asparaginase induction chemotherapy for canine lymphoma. J Vet Intern Med 2002;16:570-575.
31. Calvert CA, Leifer CE. Doxorubicin for treatment of canine lymphosarcoma after development of resistance to combination chemotherapy. J Am Vet Med Assoc 1981;171:1011-1012.
32. Buchanan G. Approach to the treatment of the febrile cancer patient with low-risk neutropenia. Hematol Oncol Clin North Am 1993;7:919-935.
33. Engervall P, Bjorkholm M. Infections in neutropenic patients I: Aetiology. Med Onco 1995;12:251-256.
34. Pizzo PA. Management of fever in patients with cancer and treatment-induced nertropenia. N Engl J Med 1993;328:1323-1332.
35. Toney JF, Parker MM. New perspectives on the management of septic shock in the cancer patient. Infect Dis Clin North Am 1996;10:239-253.
36. Berg J, Weinstein MJ, Springfield DS, et al. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555-1560.
37. Behre G, Schedel I, Nentwig B, et al. Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: Correlation with clinical outcome and determination of antiendotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins. Antimicrobial Agents & Chemotherapy 1992:36:2139-2146.
38. Okubo S, Yasunaga K. Clinical and experimental studies on DIC found in carcinoma: Correlation between anti-cancer drug administration and endotoxemia. Japanese J of Cancer Clinics 1983;29:803-806.
39. Ahaus EA, Couto CG, Valerius KD. Hematological toxicity of doxorubicin-containing protocols in dogs with spontaneously occurring malignant tumors. J Am Anim Hosp Assoc 2000;36: 422-426.
40. Kramer BS, Carr DJ, Kenneth HR, et al. Prophylaxis of fever and infection in adult cancer patients: A placebo-controlled trial of oral trimethoprim-sulfamethoxazole plus erythromycin. Cancer 1984;53:329-335.
41. Demole V. On the physiological action of ascorbic acid and some related compounds. Biochemical Journal 1934;28:770-773.
42. Cameron E, Pauling L. Cancer and Vitamin C. Menlo Park, CA: Linus Pauling Institute of Science and Medicine; 1979:1-238.
43. Kendall RV. Basic and preventative nutrition for the cat, dog and horse. In: Schoen AM. Wynn SG. eds. Complementary and Alternative Veterinary Medicine: Principles and Practice. St. Louis, MO: Mosby Inc; 1998:23-52.
44. Fiatland B. Botanicals, vitamins, and minerals and the liver: Therapeutic applications and potential toxicities. Comp Cont Ed 2003;25:514-524.
45. Figueredo AT, Hryniuk WM, Stautmanis I, et al. Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol. 1985;3:54-64.
46. McEvoy G, ed. AHFS Drug Information 2001. Bethesda, MD: American Society of Health-System Pharmacists Inc; 2001: 825-834.
47. Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Therap 2004;27:129-138.
48. Trott DJ, Filippich LJ, Bensink JC, et al. Canine model for investigating the impact of oral enrofloxacin on commensal coliforms and colonization with multidrug-resistant Escherichi coll. J Med Microbio 2004;53:439-443.
49. Karnofsky DA, Abelmann WH, Kraver LF, et al. The use of nitrogen mustards in the palliative treatment of carcinoma with particular reference to bronchogenic carcinoma. Cancer 1948;1:161-177.
50. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.